THM Capital Advisory advises Caerus Medical shareholders on its sale to Gleamer

THM Capital Advisory advised the shareholders of Caerus Medical in connection with the sale of the company to Gleamer, an international player in artificial intelligence applied to radiology.

This transaction is part of Gleamer's strategy to strengthen its position as a key innovator in medical imaging, by expanding its technological scope towards MRI.

Gleamer has acquired Caerus Medical, a pioneer company specializing in AI solutions dedicated to the diagnosis of lumbar spine pathologies using MRI.

Thanks to this acquisition, Gleamer extends its existing expertise in radiography, CT and breast imaging to magnetic resonance imaging, in order to consolidate its AI-assisted medical imaging offer.

The Caerus Medical solution was developed in three years by David Vittecoq, CEO and minority shareholder, with the financial and operational support of its majority strategic shareholder, France Imageries Territories, a French reference group in imaging.

Caerus Medical has designed advanced software that automates and improves the diagnosis of lumbar disorders based on MRIs, offering radiologists greater precision and efficiency.

Shareholders selected Gleamer as a strategic partner to support the acceleration of Caerus Medical's business growth.

As part of the transaction, David Vittecoq will continue to lead Caerus Medical, translating his confidence in the group's vision and in the potential of AI to shape the future of radiology.

This transaction is among the first external growth transactions carried out by Gleamer and is an important step in the construction of an AI-assisted diagnostics platform covering a wide range of pathologies.

THM Capital Advisory advised the sellers in the capacity of financial advisor (Thomas Mitard, Aurélien Prost, Adam Ouahid).